While no significant relationship was observed between HER2 overexpression and tumor grade or disease severity and metastases, there was a significant difference (p = 0.034) between the average specific survival in patients with HER2 overexpression (33 months) and patients with HER2 negativity (54 months) [11]. Here, ERBB2 is linked to neoplasm.